viernes, 10 de mayo de 2024

FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer (tisotumab vedotin)

https://www.news-medical.net/news/20240510/FDA-approved-TIVDAKc2ae-Targeting-tissue-factor-in-cervical-cancer.aspx

No hay comentarios:

Publicar un comentario